Mandate

Vinge advises Borgo in connection with the establishment of its MTN and covered bond programme and its inaugural issuance of MTNs

February 03, 2022 Banking and Finance

Vinge has advised Borgo AB (publ) (“Borgo”) in connection with the establishment of its SEK 50 billion MTN and covered bond programme (the “Programme”) and its inaugural issuance of SEK 1,75 billion MTNs (the “MTNs”).

The covered bonds issued under the Programme will be secured by underlying Swedish mortgage loans in accordance with the Swedish Covered Bonds Act. The MTNs carry an interest rate of STIBOR 3M + 0,90% and are intended to be listed on the corporate bond list of Nasdaq Stockholm. The Programme also caters for future issuances of green medium term notes, at the discretion of Borgo.

Borgo is a new independent mortgage lending company co-owned by ICA Banken, Ikano Bank, Söderberg & Partners and Ålandsbanken. Additional investors and Sparbanken Syd have committed to invest in Borgo. Borgo focuses on financing and offering mortgages to Swedish consumers.

Vinge’s team mainly consisted of Mikael Ståhl, Lionardo Ojeda, Axel Jansson and Felix Möller.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026